The short answer
Trial results are reported in a language designed for precision, then translated into headlines designed for attention. A few habits protect you: check how many people were treated, check how long they were followed, check whether there was a comparison group, and check whether the thing measured is the thing you care about.
Interpretation depends on phase, sample size, follow-up duration, control design and endpoint choice. Early-phase studies are typically single-arm and small, so response rates carry wide confidence intervals and lack a comparator. Surrogate endpoints — a biomarker such as protein level — may or may not predict clinical benefit. In one-time therapies, durability is a primary question that only time can answer.
Questions worth asking
- How many people? Three participants improving is a signal to investigate, not a result to rely on.
- Compared with what? Without a control group, you cannot separate the treatment from the natural course of the illness.
- Measured how? A change in a blood marker is not the same as living longer or feeling better.
- For how long? In a permanent therapy, six months of data says almost nothing about twenty years.
- Who reported it? A peer-reviewed paper, a conference abstract and a company press release are three different levels of scrutiny.
- What did the harms look like? Benefit without a serious account of adverse events is an incomplete result.
Sources
- ClinicalTrials.gov
Learn about clinical studies ↗
Check your understanding — Advanced
No score is stored and nothing is sent anywhere — this is just for you.
1. A press release reports a 90% reduction in a blood protein. What should you check first?
Why: A large effect in a handful of people over a few months is a promising signal, not proof of benefit. Size, duration and comparator decide what it means.
2. Why is multiplex editing harder than single editing?
Why: Multiple simultaneous breaks raise the risk of translocations — pieces of chromosome joining the wrong partner. Risk does not scale linearly with the number of edits.
3. What mainly drives the price of an approved cell therapy?
Why: A bespoke product made per patient, plus a hospital stay, spread across a small population, is the bulk of it — not the cost of the editing molecules.
4. CRISPR diagnostics use the technology to do what?
Why: Cas12 and Cas13 chop nearby reporter molecules once they find their target, producing a readable signal. Nothing in the patient is edited.